Abstract
Diacerein is a symptomatic slow-acting drug in osteoarthritis (SYSADOA) with anti-inflammatory, reconstructive and anti-destructive properties on cartilage and synovial membrane. Recently, based upon its mechanism of action it has been shown that it has got pro-anabolic effect on subchondral bone remodelling. Based on a literature review of clinical trials and meta-analyses, the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) declares that after the first month of osteoarthritic treatment the diacerein efficacy is superior to that of paracetamol and similar to that of non-steroidal anti-inflammatory drugs (NSAIDs). Additionally, once treatment was stopped diacerein has shown a prolonged effect on symptoms for several months, in view of its cumulative effects. Furthermore, similarly to other Symptomatic slow-acting drugs for OA (SYSADOAs), the ESCEO positions diacerein as a first-line pharmacological background treatment of osteoarthritis, particularly for patients in whom NSAIDs or paracetamol are contraindicated.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
